Original Images of Western Blotting

Effects of CC48 on tumour growth, selected as a first-in-class cannabinoid receptor type 2 (CB2R) multi-target agent. The agonist CC48 exerts its antitumour activity in gastric cancer cell models by i) binding to CB2R; ii) inhibiting the FAAH enzyme; iii) interacting with the P-gp protein responsible for the efflux of the chemotherapeutic drug paclitaxel (PTX) from the tumour cell. The main molecular pathways regulated by CC48 and involved in proliferation, autophagy and apoptosis were depicted. Previous studies have shown that the same pathways are involved in the anti-tumour activity of PTX. CC48 enhances PTX-induced cell growth inhibition, even in chemotherapy-resistant cell models.